Motoo Nomura1,2, Isao Oze3, Takeshi Kodaira4, Tetsuya Abe5, Azusa Komori6, Yukiya Narita6, Toshiki Masuishi6, Hiroya Taniguchi6, Shigenori Kadowaki6, Takashi Ura6, Masashi Andoh6, Hiroyuki Tachibana4, Norihisa Uemura5, Masahiro Tajika7, Yasumasa Niwa7, Manabu Muto8, Kei Muro6. 1. Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan. excell@hkg.odn.ne.jp. 2. Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, 606-8507, Kyoto, Japan. excell@hkg.odn.ne.jp. 3. Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan. 4. Department of Radiation Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan. 5. Department of Gastrointestinal Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan. 6. Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan. 7. Department of Endoscopy, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan. 8. Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, 606-8507, Kyoto, Japan.
Abstract
PURPOSE: Our intent was to compare survival following neoadjuvant chemotherapy followed by surgery versus chemoradiotherapy (CRT) among patients with potentially resectable esophageal squamous cell carcinoma. METHODS: Information about 406 consecutive esophageal cancer patients with resectable disease who underwent surgery with neoadjuvant chemotherapy consisting of cisplatin plus 5-fluorouracil or who underwent definitive CRT was reviewed. The survival outcomes were analyzed using the Kaplan-Meier method and propensity score-adjusted Cox proportional hazards models. Relevant variables were included in the propensity score model. RESULTS: Overall, 206 patients planned to undergo surgery (S group) and 200 patients planned to undergo CRT (CRT group). In the unadjusted situation, progression-free survival and overall survival did not differ statistically between the groups. After matching, both survival outcomes were better in the S group compared to the CRT group. Subanalysis showed both survival outcomes were better in the S group for patients with only stage III disease. However, survival outcomes for stages I, II, and IV were not significantly different between treatment groups. CONCLUSIONS: Among patients with resectable disease, survival outcomes in the S group were favored over those of the CRT group. These results indicate that different therapeutic strategies should be used for stage III esophageal cancer than for other stages.
PURPOSE: Our intent was to compare survival following neoadjuvant chemotherapy followed by surgery versus chemoradiotherapy (CRT) among patients with potentially resectable esophageal squamous cell carcinoma. METHODS: Information about 406 consecutive esophageal cancerpatients with resectable disease who underwent surgery with neoadjuvant chemotherapy consisting of cisplatin plus 5-fluorouracil or who underwent definitive CRT was reviewed. The survival outcomes were analyzed using the Kaplan-Meier method and propensity score-adjusted Cox proportional hazards models. Relevant variables were included in the propensity score model. RESULTS: Overall, 206 patients planned to undergo surgery (S group) and 200 patients planned to undergo CRT (CRT group). In the unadjusted situation, progression-free survival and overall survival did not differ statistically between the groups. After matching, both survival outcomes were better in the S group compared to the CRT group. Subanalysis showed both survival outcomes were better in the S group for patients with only stage III disease. However, survival outcomes for stages I, II, and IV were not significantly different between treatment groups. CONCLUSIONS: Among patients with resectable disease, survival outcomes in the S group were favored over those of the CRT group. These results indicate that different therapeutic strategies should be used for stage III esophageal cancer than for other stages.
Entities:
Keywords:
Chemoradiotherapy; Esophageal cancer; Neoadjuvant chemotherapy; Propensity score analysis; Surgery
Authors: A Herskovic; K Martz; M al-Sarraf; L Leichman; J Brindle; V Vaitkevicius; J Cooper; R Byhardt; L Davis; B Emami Journal: N Engl J Med Date: 1992-06-11 Impact factor: 91.245
Authors: A Ohtsu; N Boku; K Muro; K Chin; M Muto; S Yoshida; M Satake; S Ishikura; T Ogino; Y Miyata; S Seki; K Kaneko; A Nakamura Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Bruce D Minsky; Thomas F Pajak; Robert J Ginsberg; Thomas M Pisansky; James Martenson; Ritsuko Komaki; Gordon Okawara; Seth A Rosenthal; David P Kelsen Journal: J Clin Oncol Date: 2002-03-01 Impact factor: 44.544
Authors: T W Rice; V W Rusch; C Apperson-Hansen; M S Allen; L-Q Chen; J G Hunter; K A Kesler; S Law; T E M R Lerut; C E Reed; J A Salo; W J Scott; S G Swisher; T J Watson; E H Blackstone Journal: Dis Esophagus Date: 2009 Impact factor: 3.429
Authors: Arianna Barbetta; Meier Hsu; Kay See Tan; Dessislava Stefanova; Koby Herman; Prasad S Adusumilli; Manjit S Bains; Matthew J Bott; James M Isbell; Yelena Y Janjigian; Geoffrey Y Ku; Bernard J Park; Abraham J Wu; David R Jones; Daniela Molena Journal: J Thorac Cardiovasc Surg Date: 2018-02-15 Impact factor: 5.209